{"@context":{"@vocab":"https://schema.org/"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/fda/warning-letters/check?name=Samm%20Solutions%2C%20Inc.%2C%20d.b.a.%20BTS%20Research","name":"Samm Solutions, Inc., d.b.a. BTS Research","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://creativecommons.org/publicdomain/zero/1.0/","primary_source":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters","generated_at":"2026-10-06T06:26:43.034Z"},"count":1,"matches":[{"id":"1bc032e423840c43","posted_date":"2023-10-31","letter_issue_date":"2023-10-20","company_name":"Samm Solutions, Inc., d.b.a. BTS Research","issuing_office":"Center for Drug Evaluation and Research | CDER","subject":"Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies","canonical_url":"https://api.morvs.ai/fda-warning/1bc032e423840c43"}]}